Rh Disease & Humanitarian MissionWhite Paper
History of Rh Prevention
Traces Rh Hemolytic Disease from its 65,000-year origins to RhoGAM's 1968 breakthrough and the unfinished mission to extend protection to the Global South.
Read MoreIntellectual Property Archive
High Financewith a Heart
TC-IP is the working archive of Dr. John Gorman — inventor of RhoGAM and pioneer in laboratory automation. His work on Rh Immune Globulin helped eliminate Rh Disease across the developed world beginning in 1968, yet the disease still kills more than 140,000 newborns annually in low-income countries where treatment remains unavailable. In the final chapter of his career, Dr. Gorman turned from medical invention to financial systems design: developing TCRA, a licensing and royalty model intended to fund the global eradication of Rh Disease without relying solely on traditional philanthropy.
Lasker Award Recipient · RhoGAM Co-Inventor · Pioneer in Laboratory Automation
Start Here
Recommended Reading
New to the archive? These five documents cover the full story — the disease, the man, and the plan.
01Summary
TCRA Deal Summary
The clearest single-page explanation of the plan — read this first.
Read More →02Strategy
The Rh Club Strategy
How a group of billionaire philanthropists — the Rh Club — becomes the access channel that gets the TCRA opportunity in front of Big 4 leadership.
Read More →03Deposition
John Gorman's Deposition
Dr. Gorman at 94, in his own words — the discovery, the regret, and the new idea.
Read More →04Research
Rh Disease in the Global South
Quantifies the disease burden in low-income regions, where HDFN prevalence reaches 529 per 100,000 births versus 2.5 per 100,000 in developed nations.
Read More →05White Paper
The ILBOW
The financial structure that makes it all possible — zero cost, infinite leverage, no debt.
Read More →Browse all 36 documents in the full archive below →
Full Archive
Patents, White Papers & STRATEGIES
Rh Disease & Humanitarian MissionResearch
Rh Disease in the Global South
Quantifies the disease burden in low-income regions, where HDFN prevalence reaches 529 per 100,000 births versus 2.5 per 100,000 in developed nations.
Read MoreRh Disease & Humanitarian MissionArticle
Legacy Unfulfilled (Columbia Magazine)
Columbia Medicine feature on Dr. Spitalnik, Dr. Gorman, and WIRhE's mission to close the global gap in anti-D immunoglobulin access.
Read MoreRh Disease & Humanitarian MissionData Model
Babies Dying Projection Model
Projects annual Rh-related infant deaths in the Global South under different funding and prevention rollout scenarios.
Read MoreRh Disease & Humanitarian MissionDeposition
John Gorman's Deposition
Dr. Gorman's first-person account at 94 of the RhoGAM discovery, the unfinished global mission, and the TCRA high-finance solution.
Read MoreRh Disease & Humanitarian MissionInterview
Andrew Probyn Interview Script
Long-form interview script profiling Dr. Gorman's career and the TCRA plan to fund WIRhE with a $10 billion endowment.
Read MoreThe TCRA PlanMaster Plan
TCRA Plan
The master document defining TCRA's seven action parties, the $1 trillion royalty mechanism, and the closed-loop value chain that funds WIRhE.
Read MoreThe TCRA PlanNarrative
The TCRA Story
Narrative explaining how TCRA's patents, the Big 4 oligopoly, and a single announcement event can create $300 billion in value in one day.
Read MoreThe TCRA PlanSummary
Concise TCRA Plan
A condensed walkthrough of the TCRA business plan: the Big 4 DLA announcement, the $300 billion valuation, and the path to a WIRhE endowment.
Read MoreThe TCRA PlanSummary
TCRA Deal Summary
Outlines the three core TCRA assumptions and the Payday Signing Conference structure where all parties commit simultaneously.
Read MoreThe TCRA PlanSummary
TCRA Barebones
A seven-bullet distillation of the entire TCRA thesis: market size, patent leverage, Big 4 oligopoly, and underwriter role.
Read MoreThe TCRA PlanConcept
TCIP — The TCRA Charitable Donation Plan
Frames TCRA as a charitable donation plan that channels patent-driven royalties to WIRhE and major foundations through Big 4 adoption.
Read MoreThe TCRA PlanConcept
TCRA Deal
Examines the high-finance structure of TCRA under the premise that the three core assumptions hold, focused on closing mechanics.
Read MoreThe TCRA PlanNarrative
TCRA Plan Narrative & List of Factors
Pairs the step-by-step deal sequence with the extraordinary confluence of factors that uniquely enables TCRA right now.
Read MoreThe TCRA PlanFramework
Confluence of Factors
Catalogs the rare alignment of conditions — the patents, the oligopoly, the market size, the Rh Club, the secondary markets — that makes TCRA possible.
Read MoreThe TCRA PlanConcept
Uniqueness of the TCRA Deal
Argues why TCRA is unprecedented in scale and structure, and why no other path can fund WIRhE at the required level.
Read MoreThe TCRA PlanFramework
TCRA's Benefits
Enumerates the Goldilocks benefits TCRA delivers to every stakeholder — zero donations required, infinite leverage, infinite ROI.
Read MoreThe TCRA PlanConcept
Four TCRA Facts
The four foundational facts: Big 4 can create $300B in value at one stroke, convert global labs, raise hundreds of billions, and need investor access.
Read MoreThe TCRA PlanFramework
The Three TCRA Assumptions
Defines the three assumptions the plan rests on: Big 4 will adopt DLA, will announce it, and TCRA will be valued at $300 billion.
Read MoreThe TCRA PlanFramework
The 9 TCRA Assumptions
Expanded analysis of nine operational, financial, regulatory, and market assumptions underlying the TCRA business plan.
Read MoreThe TCRA PlanConcept
Conversation with Gemini on the 3 TCRA Assumptions
An AI-assisted stress test of the three core TCRA assumptions, examining risks, dependencies, and counterarguments.
Read MoreThe TCRA PlanConcept
A New VC Idea
Reframes TCRA as a new venture capital model: invite large incumbents and top financiers to co-create instant value before any operations.
Read MoreFinancial StrategyWhite Paper
The ILBOW
Defines the Infinite Leverage Buy Out Without Debt — the structure that lets the Big 7 acquire TCRA at zero cost and create $300 billion in value through one announcement.
Read MoreFinancial StrategyDeck
The ILBOW Presentation
Slide deck explaining the ILBOW mechanism, the Big 7 structure, and the path from zero-value shares to $300B+ company valuation.
Read MoreFinancial StrategyDeck
TCRA Deck
Master pitch deck framing TCRA as a Special Situation: $1T royalty potential, $300B valuation, $0 acquisition cost.
Read MoreFinancial StrategyStrategy
TCRA Fund Raising
Details the three TCRA share sales programs — First Series, Second Series, and Third Series — that convert announcement-driven value into cash.
Read MoreFinancial StrategyStrategy
Post-Announcement Share Sales
Specifies the two investor rounds U3 underwriters will run to raise $20B at $100B valuation, then $20B at $300B valuation, post-announcements.
Read MoreFinancial StrategyFinancial Model
TCRA Royalties Spreadsheet
Twenty-year DCF model of clinical lab revenues, DLA market penetration, royalty cash flow, and present value per TCRA share.
Read MoreStakeholdersConcept
What's in it for the Big 7
Lays out the financial, strategic, and reputational rewards the Big 7 — Big 4 manufacturers plus the three underwriters — receive for participating.
Read MoreStakeholdersConcept
What's in it for the Underwriter Firms
Explains why Morgan Stanley, Blackstone, and Andreessen Horowitz have a once-in-a-generation incentive to underwrite TCRA.
Read MoreStakeholdersStrategy
The Rh Club Strategy
How a group of billionaire philanthropists — the Rh Club — becomes the access channel that gets the TCRA opportunity in front of Big 4 leadership.
Read MoreStakeholdersStrategy
Big 4 Corporate Development
Strategic discussion of how Siemens, Roche, Abbott, and Danaher can deploy and commercialize DLA globally once they commit.
Read MoreStakeholdersPress Release
Abbott DLA Press Release (Draft)
Draft announcement showing how Abbott — and the other Big 4 — would frame their commitment to replace TLA with TCRA-patented DLA.
Read MoreTechnology & PatentsWhite Paper
Team Conveyer Technology
Technical white paper on Team Conveyer architecture — the patented robotics platform behind Dark Lab Automation and the TableTop analyzer.
Read MoreTechnology & PatentsPatent
US Patent 12,282,036 — Total Lab Automation System
Granted U.S. patent for the Total Lab Automation System: coordinated multi-axis conveyors and station-based processing on a tabletop surface.
Read MoreTechnology & PatentsPortfolio
TCRA Patent Portfolio
The full TCRA intellectual property portfolio: US, PCT, and international filings covering coordinated conveyors, storage, and total lab automation.
Read MoreShowing 36 of 36 entries
The Legacy
He Helped Eliminate Rh Disease
in the Developed World
Now he is working to finish the job.
Lasker Award · 1980
Highest US medical honor
Early laboratory work · 1960s
The breakthrough that changed global medicine
Founder, TCRA
Dr. John Gorman
In 1959, as a pathology resident at Columbia University, Dr. Gorman had the key insight that led to the development of RhoGAM — the drug that has prevented Rh Hemolytic Disease in the developed world since 1968, saving an estimated 9 million babies' lives.
Working with Dr. Vincent Freda at Columbia and Dr. William Pollack at Ortho Pharmaceuticals, he showed that passive immunization with anti-D immunoglobulin could prevent sensitization entirely. RhoGAM was approved by the FDA in 1968 and became the global standard of care. Dr. Gorman received the Albert Lasker Clinical Medical Research Award in 1980. He holds more than 20 US and international patents and is now 94.
20+
Patents Filed/Granted
9 Million
Babies' Lives Saved Since 1968
$750M+
Annual Healthcare Savings (US)
60+ yrs
Of Medical Innovation
The Unfinished Problem
The science exists.
The treatment exists.
But the funding and logistics to deliver it globally do not.
"A solved disease — still unsolved at global scale."
The Plan
140,000 babies still die from Rh disease every year — almost entirely in Africa and Southeast Asia — because the $250 million needed annually to distribute the treatment at scale has never been raised.
Dr. Gorman's answer is not a fundraising campaign. Through his patent-holding company TCRA, he has designed a high-finance structure that would generate $1 trillion in royalties from the global clinical laboratory industry over 20 years — directing $10 billion immediately to WIRhE, the nonprofit built to eradicate Rh disease worldwide.
No donations required. The archive on this site documents both the technology and the plan.
Dr. Gorman — a lifetime of recognition for transforming global healthcare
Get In Touch
Laboratory Automation.
Humanitarian Finance.
Dr. Gorman is 94 and still working. If you represent a clinical lab manufacturer, a private equity or venture firm, a major foundation, or a global health organization — and you've read the archive — he wants to hear from you.
The TCRA plan requires a small number of the right people in the right rooms. Agency is the only thing missing.
Patent licensing & DLA technology inquiries
TCRA investment & underwriting conversations
WIRhE funding & global health partnerships
Speaking engagements & media
Direct Contact
Dr. John Gorman
Founder, TC-IP & TCRA
Dr. Gorman personally reviews all inquiries. Response times may vary based on availability.